EGFR-TKI The personalized anti-cancer agent screening system and process for EGFR-TKI resistant patients using the circulating tumor cells derived on patients with the lung cancer

摘要

The present invention relates to a system for screening anti-cancer drug candidates for patients with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) resistance using circulating tumor cells (CTCs) The present invention relates to a screening method, and more particularly, to a method for separating blood circulating tumor cells from the blood of a patient suffering from epithelial growth factor receptor tyrosine kinase inhibitor using a rare cell separator, The present invention relates to a system and a method for selecting a personalized anticancer agent.;